信达证券发布圣诺生物研报，受益于多肽产业链景气度，中长期成长性突出

Group 1 - The core viewpoint of the report highlights that Shengnuo Biotech (688117.SH) benefits from the favorable conditions in the peptide industry chain, leading to significant year-on-year growth in its raw material drug business and CDMO (Contract Development and Manufacturing Organization) business [2] - The company's capacity construction is becoming increasingly complete, indicating outstanding medium to long-term growth potential [2] Group 2 - The report mentions potential risks, including the possibility of new orders falling short of expectations, fluctuations in raw material drug prices, and risks associated with geopolitical and tariff changes [2]